BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc. is a U.S.-based AI/ML company focused on applying machine learning to complex biomedical data to support drug discovery and development. The company’s core platform, bfLEAP™, originated from technology developed at The Johns Hopkins University Applied Physics Laboratory and has since been expanded with additional models and tools. BullFrog AI combines software-driven analytics services with a broader strategy of partnering with biopharma companies and, longer term, acquiring drug rights and using its platform to accelerate development. The business is still early-stage and pre-commercial at scale, with limited revenue history and a continuing need for external financing to fund operations.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenuebfLEAP™ and related machine-learning tools used to analyze complex medical and life-science datasets.
Custom analysis engagements for drug discovery, target identification, and workflow integration.
Partnerships with biopharma and research organizations structured around fees, equity, or IP.
Acquired or licensed drug candidates advanced using the company’s AI/ML capabilities.
Customers
BullFrog AI sells primarily to biopharma companies that want to reduce the time, cost, and risk of drug development by using AI/ML to interrogate complex datasets. Its collaboration model suggests customers may pay in cash, equity, or other consideration depending on the scope and strategic value of the engagement. The company also works with research-oriented partners and public or proprietary health-data sources to improve model performance and expand its analytical capabilities. In the longer term, the company’s drug-asset strategy implies it may also create value through partnerships around acquired or in-licensed programs rather than only through pure software sales.
Drug developers that buy analytical services and platform access to reduce development risk and speed decision-making.
Partners around in-licensed or acquired drug assets that need AI/ML support to advance candidates toward value-creating milestones.
Organizations that provide datasets, validation, or scientific collaboration to strengthen the platform and expand use cases.
Data owners that enable new discovery workflows and improve model training and analytical depth.
Strategy
BullFrog AI’s near-term strategy is to generate revenue through strategic relationships with biopharma companies, using its AI/ML platform to deliver insights that reduce drug-development risk and accelerate workflows. The company is willing to structure engagements flexibly, including cash, equity, or IP-based consideration, which can help win early partnerships but also adds variability to revenue quality. A second strategic pillar is to acquire rights to drug assets at different development stages and use bfLEAP™ to create near-term value before monetizing the programs, ideally within about 30 months. This strategy is designed to combine software-like analytics revenue with higher-upside asset development, but it requires capital, execution discipline, and scientific validation.
Partnership revenue is the company’s main near-term commercialization path and helps validate the platform.
Improving the AI/ML platform increases the quality of insights and strengthens differentiation in drug discovery analytics.
Owning or licensing programs can create higher-value monetization opportunities than services alone.
Geography
BullFrog AI is headquartered in the United States and its operations are currently conducted through its U.S. corporate entities. The company’s reported business activity is centered on domestic R&D, collaboration development, and customer engagement rather than a broad international operating footprint. Because the company is early-stage, geography matters mainly through access to U.S. capital markets, U.S.-based scientific partners, and U.S. health-data sources. No country-level revenue concentration was disclosed in the provided excerpts, so the geographic profile should be viewed as operationally U.S.-centric with limited disclosed international exposure.
Risks
BullFrog AI faces substantial going-concern and financing risk because it has limited recurring revenue and has stated that current cash is not sufficient to fund planned operations for at least a year. The company also disclosed unremediated material weaknesses in internal control over financial reporting, which increases the risk of reporting errors and can complicate access to capital. Commercial execution risk is high because the business depends on winning a small number of strategic biopharma collaborations and proving that its AI/ML outputs create measurable value. More broadly, AI-enabled drug discovery is a competitive and scientifically uncertain market, so the company faces the risk that models do not translate into successful development outcomes, partner demand remains limited, or funding conditions tighten.
The company disclosed that cash is not sufficient to fund planned operations for at least a year and it has no committed future funding.
Management reported unremediated material weaknesses in financial reporting controls, increasing the risk of misstatement and delayed reporting.
Exposure: Financial reporting and investor confidence
Revenue depends on a limited number of biopharma collaborations and the company has only a short commercial history.
Exposure: Revenue stability and pipeline visibility
The platform must prove that its analytics improve drug-development outcomes, which is inherently uncertain and data-dependent.
Exposure: Product adoption and asset value creation
Accounting
Judgemental itemsEngagements may include cash, equity, or other consideration, so timing and fair value judgments can affect reported revenue.
Impact: Can shift revenue between periods and affect comparability
If contracts include equity or IP-based consideration, management must estimate fair value using judgmental assumptions.
Impact: Can materially affect reported revenue and other income
Unremediated material weaknesses raise the risk that estimates, accruals, and disclosures are not fully reliable.
Impact: Affects confidence in all reported financial statement line items
Liquidity disclosures and financing assumptions are central to evaluating whether the company can continue operations.
Impact: Influences investor assessment of solvency and dilution risk
Similar listed companies
Publicly listed companies with a comparable business focus.
JFrog Ltd
FROG · Services-Prepackaged Software
JFrog Ltd builds a software supply chain platform that helps enterprises store, secure, govern, and continuously deliver software artifacts from code to production.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
BMP Ai Technologies, Inc.
BMPA · Services-Motion Picture & Video Tape Production
Simulations Plus, Inc.
SLP · Services-Computer Integrated Systems Design
Helport AI Ltd
HPAIW · Services-Prepackaged Software
Helport AI Ltd is a U.S.-listed software services company incorporated in the British Virgin Islands and based in Singapore.
Bubblr Inc.
BBLR · Services-Computer Programming, Data Processing, Etc.
Bubblr Inc., which also operates under the Ethical Web AI name, is a U.S.-based artificial intelligence company built around patent-protected software and search technologies.
Last updated: 11/08/2026